Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

To evaluate the safety and tolerability of ERAS-601. To determine the ERAS-601 Maximum Tolerated Dose (MTD) and/or recommended dose (RD) as a monotherapy and in combination with a MEK inhibitor. To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with a MEK inhibitor.

Sarah Cannon Research Institute (Florida Cancer Specialists)
 (4.8 away) Contact site
  • 0 views
  • 30 May, 2021
  • +5 other locations
A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-585, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study consists of 2 parts, a …

Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 26 May, 2021
  • +2 other locations
Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).

Sarah Cannon Research Institute
 (5.4 away) Contact site
  • 0 views
  • 16 May, 2021
  • +10 other locations
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label, multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in participants with selected, advanced or recurrent solid tumors with the aim …

gemcitabine
solid neoplasm
combinations
pembrolizumab
measurable disease
GSK Investigational Site
 (5.4 away) Contact site
  • 0 views
  • 26 Jan, 2021
  • +29 other locations
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of MGD013. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of MGD013 will also be assessed.

cancer
solid tumour
HER2
erbb2
measurable disease
Florida Cancer Specialists & Research Institute
 (5.4 away) Contact site
  • 534 views
  • 17 Feb, 2021
  • +69 other locations
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab combination therapy will be for up to 35 administrations (approximately 2 …

cancer
antineoplastic
lung cancer
mk-3475
pembrolizumab
Florida Cancer Specialists ( Site 0002)
 (4.8 away) Contact site
  • 283 views
  • 17 Feb, 2021
  • +10 other locations
A Study of XmAb 23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

cervical carcinoma
solid tumour
cancer
ipilimumab
monoclonal antibodies
Florida Cancer Specialists
 (5.4 away) Contact site
  • 133 views
  • 25 May, 2021
  • +14 other locations
Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer and triple negative breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer and triple negative breast cancer.

cancer
gilbert's syndrome
formalin-fixed paraffin-embedded
stage iv breast cancer
breast cancer
Florida Cancer Specialists & Research Institute
 (5.4 away) Contact site
  • 8 views
  • 23 May, 2021
  • +7 other locations
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Florida Cancer Specialists
 (6.3 away) Contact site
  • 38 views
  • 27 Jan, 2021
  • +3 other locations
RBN-2397 an Oral PARP7 Inhibitor in Patients With Solid Tumors FIH MAD Study

RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and …

cancer
solid tumour
solid tumor
breast cancer
lymphoma
SCRI-Sarasota/Florida Cancer Specialists
 (5.4 away) Contact site
  • 0 views
  • 15 May, 2021
  • +5 other locations